Adult Immunization

Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.

The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.

The FDA advisory committee will review all current surveillance data and recommend which strain/s to include in updated COVID-19 vaccines for the 2023-2024 vaccination campaign.

The FDA has approved 2 vaccines against respiratory syncytial virus in older adults—with final details pending. This 2-question quiz tests how closely you've been following.

Need more talking points to help patients grasp the importance of the bivalent COVID-19 vaccine? The answers to these 3 questions should help.

Medical director of the NFID William Schaffner, MD, shares 3 things about the RSV vaccine that should be top of mind for primary care clinicians.

The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.

Delivering 3 vaccines to older adults is going to be a challenge this fall, says Dr William Schaffner.

Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.

Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.

Medical director of the NFID William Schaffner, MD, discusses the research behind the FDA's decision to approve the first-ever RSV vaccine.

Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.

Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."

Neutralizing antibodies were lowest among Janssen volunteers at 1 month post-vaccination but at 6 months afterward, the picture was much different.

New CDC recommendations for pneumococcal vaccination for persons aged 19 to 64 years could require some extra thought. This 4-question quiz tests your knowledge.

Reducing American's risk for CHD and cardiovascular events gets harder as the population ages and obesity rates climb. Can a vaccine help?

Tirzepatide delivers 15.7% weight loss in adults with obesity; remote intervention increases cancer screening in women; women at greater post-MI risk vs men; plus 2 more updates of note.

The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.

The FDA action ends the use of monovalent COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna in favor of bivalent formulations to simplify the vaccination schedule, said the Agency.

Ensitrelvir fast track status is supported by phase 3 study findings showing resolution of COVID-19 symptoms a full day earlier in those taking the drug vs placebo.

Onset of the 2022-2023 RSV season and its end were closer to historical patterns but atypical circulation may continue, say researchers writing in MMWR.

Vaccine side effects are usually trouble when they make the news. But sometimes, an unexpected result has merit. Find out more.

Universal vaccination against chickenpox with a live-attenuated varicella vaccine began 25 years ago. Were concerns about future shingles outbreaks borne out?

Your daily dose of clinical news you may have missed.

Research on myocarditis has found the risk for the condition significantly higher from infection with SARS-CoV-2 vs from mRNA vaccination against it. True or False?

For vaccine-hesitant patients concerned about myocarditis, it may be helpful to provide real-world context. The quiz contains tips on how to do that.

ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.

Data presented at CROI 2023 demonstrated that periods of reinfection with the virus correlated with ascent of new variants and with time since first infection.

The VRBPAC vote that the GSK data support the vaccine's efficacy was unanimous and on safety the vote was 10-2. PDUFA date set for May, 2023.

The study of more than 1.9 million US residents is the first to investigate a link between both full and partial COVID-19 vaccination and future CV risk.